Seres Therapeutics (MCRB) Expected to Announce Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) is anticipated to post its Status update results before the market opens on Thursday, March 12th. Analysts expect Seres Therapeutics to post earnings of ($2.39) per share for the quarter. Parties may visit the the company’s upcoming Status update earning results page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:30 AM ET.

Seres Therapeutics Price Performance

Shares of MCRB opened at $9.32 on Tuesday. Seres Therapeutics has a 1-year low of $6.53 and a 1-year high of $29.98. The stock has a market cap of $84.35 million, a price-to-earnings ratio of -2.61 and a beta of 0.32. The firm has a 50 day simple moving average of $12.81 and a 200-day simple moving average of $16.04.

Hedge Funds Weigh In On Seres Therapeutics

Institutional investors have recently modified their holdings of the company. Marshall Wace LLP purchased a new position in shares of Seres Therapeutics during the second quarter valued at approximately $1,016,000. Invesco Ltd. grew its stake in Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 89,995 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in Seres Therapeutics in the 3rd quarter valued at $557,000. Goldman Sachs Group Inc. raised its holdings in Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 21,679 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Seres Therapeutics by 6.8% during the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock worth $6,001,000 after purchasing an additional 19,793 shares during the period. Institutional investors and hedge funds own 59.34% of the company’s stock.

Wall Street Analysts Forecast Growth

MCRB has been the topic of a number of analyst reports. Wall Street Zen cut Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Weiss Ratings reissued a “sell (d)” rating on shares of Seres Therapeutics in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $14.33.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.